Research programme: Nanobodies therapeutics - Ablynx/Boehringer Ingelheim

Drug Profile

Research programme: Nanobodies therapeutics - Ablynx/Boehringer Ingelheim

Latest Information Update: 04 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ablynx
  • Class Bispecific antibodies; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Autoimmune disorders; Cancer; Respiratory tract disorders

Most Recent Events

  • 09 Oct 2013 A lead compound from this programme has entered clinical development for Alzheimer's disease
  • 20 Mar 2012 Ablynx and Boehringer Ingelheim extend their licensing agreement until 2014
  • 08 Dec 2010 Nanobody candidate selected by Boehringer Ingelheim for development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top